StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research note published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Performance
Aeterna Zentaris stock opened at $6.01 on Monday. The company has a market cap of $10.78 million, a P/E ratio of -0.40 and a beta of 1.55. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.00. The business has a fifty day moving average of $5.73 and a two-hundred day moving average of $7.18.
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last issued its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share (EPS) for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
Further Reading
- Five stocks we like better than Aeterna Zentaris
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Jeff Brown’s Exegesis AI Stock Picks
- What is a Secondary Public Offering? What Investors Need to Know
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.